Reflections on ASH 2015 From Dr. Susan O’Brien On location at the American Society of Hematology (ASH) 2015 meeting, CLL expert Dr. Susan O’Brien of the University of California, Irvine, answers several questions about frontline treatment for patients at different stages of CLL. Dr. O’Brien discusses treatment for relapsed-refractory patients, toxicity concerns and 17p deletion, as well as shares her excitement for possible FDA approval by 2017 for rituximab (Rituxan) in combination treatments. Get email alerts | Subscribe on YouTube | Like on Facebook | Follow on Twitter | Follow on Google+ |